Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)
Inhibikase Therapeutics' (IKT) quarterly EBITDA Margin came in at 440356600.0% in Q4 2023, down 44034978036.0% year-on-year from N/an in Q4 2022, and down 7347277.94% on a QoQ basis from 5993.38% in Q3 2023.
Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of EBITDA Margin data on file, last reported at 440356600.0% in Q4 2023.
- On a quarterly basis, EBITDA Margin fell 44034978036.0% year-over-year to 440356600.0% in Q4 2023; TTM through Sep 2024 was 2006393700.0%, a 200638752188.0% decrease from a year earlier, with the FY2023 full-year figure at 7711.98%, up 697419.0% from the prior year.
- EBITDA Margin for Q4 2023 stood at 440356600.0%, down from 5993.38% in the prior quarter.
- Over the last five years, EBITDA Margin for IKT reached as high as 186.56% in Q1 2021 and fell as low as 440356600.0% in Q4 2023.
- Historically, EBITDA Margin has averaged 27549298.5% across 4 years, with a median of 5660.72% in 2023.
- Across the five-year window, EBITDA Margin jumped 25251477 bps in 2022 and sank 2000000000 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 704.66% in 2020, then plunged by 36703 bps to 259334.41% in 2021, then surged by 97 bps to 6819.64% in 2022, then sank by 6457080 bps to 440356600.0% in 2023.
- Per Business Quant data, the three most recent EBITDA Margin figures were 440356600.0% in Q4 2023, 5993.38% in Q3 2023, and 5328.07% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -5,993.38% |
| Jun 30, 2023 | -5,328.07% |
| Mar 31, 2023 | -7,307.62% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -61,899.59% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.46% |
| Dec 31, 2021 | -259,334.41% |
| Sep 30, 2021 | -1,361.22% |
| Jun 30, 2021 | -192.83% |
| Mar 31, 2021 | -186.56% |
| Dec 31, 2020 | -704.66% |
| Sep 30, 2020 | -1,761.44% |
| Jun 30, 2020 | -188.50% |
| Mar 31, 2020 | -199.42% |